daclizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
human origin 4953 152923-56-3

Description:

MoleculeDescription

Synonyms:

  • zinbryta
  • daclizumab
  • zenapax
An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) humanized monoclonal antibody (immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used in the treatment of ACUTE RELAPSING MULTIPLE SCLEROSIS.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
5 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Dec. 10, 1997 FDA HOFFMAN-LA ROCHE
Feb. 26, 1999 EMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Transplant dysfunction 2541.82 45.41 405 4610 4877 90618555
Transplant rejection 1999.55 45.41 376 4639 12382 90611050
Ovarian cyst 1812.50 45.41 364 4651 16954 90606478
Acne 1648.22 45.41 367 4648 28140 90595292
Alopecia 764.20 45.41 418 4597 494653 90128779
Liver function test abnormal 455.43 45.41 151 4864 50694 90572738
Multiple sclerosis relapse 312.61 45.41 115 4900 52190 90571242
Sleep disorder due to general medical condition, insomnia type 297.98 45.41 144 4871 128550 90494882
Rheumatoid arthritis 179.66 45.41 153 4862 362461 90260971
Pneumonia 144.04 45.41 176 4839 637883 89985549
Condition aggravated 117.88 45.41 154 4861 595391 90028041
Loss of personal independence in daily activities 112.36 45.41 78 4937 136027 90487405
Kidney transplant rejection 97.80 45.41 27 4988 4830 90618602
Overdose 97.67 45.41 76 4939 157633 90465799
Pain 84.91 45.41 176 4839 996165 89627267
Incorrect route of product administration 77.40 45.41 43 4972 50583 90572849
Product use issue 52.43 45.41 77 4938 329842 90293590
Drug ineffective 50.60 45.41 179 4836 1384119 89239313

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 150.88 38.32 36 584 14228 42606487

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Transplant dysfunction 2450.21 43.42 409 4800 7919 110576171
Ovarian cyst 1955.98 43.42 365 4844 13565 110570525
Transplant rejection 1796.06 43.42 373 4836 24194 110559896
Acne 1647.37 43.42 367 4842 33153 110550937
Alopecia 942.66 43.42 416 4793 364337 110219753
Liver function test abnormal 437.98 43.42 152 5057 68798 110515292
Sleep disorder due to general medical condition, insomnia type 347.44 43.42 144 5065 105499 110478591
Multiple sclerosis relapse 346.96 43.42 118 5091 50122 110533968
Rheumatoid arthritis 225.24 43.42 152 5057 299461 110284629
Pneumonia 126.68 43.42 179 5030 876535 109707555
Condition aggravated 118 43.42 158 5051 734678 109849412
Loss of personal independence in daily activities 116.86 43.42 78 5131 149942 110434148
Pain 105.25 43.42 172 5037 954783 109629307
Overdose 90.11 43.42 80 5129 233714 110350376
Incorrect route of product administration 74.41 43.42 43 5166 64018 110520072
Product use issue 70.73 43.42 80 5129 311615 110272475
Drug ineffective 57.72 43.42 179 5030 1520361 109063729
Encephalitis autoimmune 48.26 43.42 14 5195 3514 110580576

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AC01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Interleukin inhibitors
FDA MoA N0000010279 Interleukin 2 Receptor Antagonists
MeSH PA D007155 Immunologic Factors
MeSH PA D007166 Immunosuppressive Agents
FDA MoA N0000175621 Interleukin 2 Receptor-directed Antibody Interactions
FDA EPC N0000175622 Interleukin-2 Receptor Blocking Antibody
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:50748 antipsoriatic
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:65023 anti-asthmatic agent
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:75835 anti-anaemic agent
CHEBI has role CHEBI:231911 renoprotective agent

Related Drugs by ATC class:

L04AC Interleukin inhibitors 18 drugs
anakinrabasiliximabbimekizumabbrodalumabcanakinumabguselkumabixekizumabmirikizumabrilonaceptrisankizumabsarilumabsatralizumab show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Renal transplant rejection indication 236570004
Relapsing remitting multiple sclerosis indication 426373005 DOID:2378




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interleukin-2 receptor Membrane receptor ANTIBODY BINDING Kd 8 IUPHAR DRUG LABEL

External reference:

IDSource
D03639 KEGG_DRUG
4021083 VUID
N0000148541 NUI
4021083 VANDF
CHEBI:749553 CHEBI
CHEMBL1201605 ChEMBL_ID
6880 IUPHAR_LIGAND_ID
DB00111 DRUGBANK_ID
1795335 RXNORM
11508 MMSL
241453 MMSL
4529 MMSL
d04262 MMSL
007284 NDDF
109133001 SNOMEDCT_US
386977009 SNOMEDCT_US
C0663182 UMLSCUI
D000077561 MESH_DESCRIPTOR_UI
7164 INN_ID
CUJ2MVI71Y UNII

Pharmaceutical products:

None